(Reuters) - Valeant Pharmaceuticals International Inc (N:VRX) (TO:VRX), under scrutiny for its accounting and business practices, said it had given shareholder Pershing Square (NYSE:SQ) Capital Management a seat on its board and added two additional directors.
Stephen Fraidin, a veteran Wall Street lawyer who is vice chairman at William Ackman's Pershing Square, has joined the board, along with Fred Eshelman and Thomas Ross, Valeant said.
Anders Lonner has stepped down as a director, the company said on Wednesday.